Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder

European Urology

Volumn 65, Issue 1, 2014, Pages 201-209

  Rieken, Malte ^a,b   Xylinas, Evanguelos ^a,c   Kluth, Luis ^a,d   Crivelli, Joseph J ^a   Chrystal, James ^a   Faison, Talia ^a   Lotan, Yair ^e   Karakiewicz, Pierre I ^f   Holmäng, Sten ^g   Babjuk, Marek ^h   Fajkovic, Harun ⁱ   Seitz, Christian ⁱ   Klatte, Tobias ⁱ   Pycha, Armin ^j   Bachmann, Alexander ^b   Scherr, Douglas S ^a   Shariat, Shahrokh F ^a,i  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Institut Cochin   (France)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j CENTRAL HOSPITAL OF BOLZANO   (Italy)

more..

Author keywords

Immediate postoperative intravesical chemotherapy; Outcome assessment; TaG1 urothelial carcinoma of the bladder; Transurethral resection

Indexed keywords

DOXORUBICIN; EPIRUBICIN; MITOMYCIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; CANCER STAGING; CARCINOMA, TRANSITIONAL CELL; DISEASE COURSE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; TIME; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

AGED; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84888825186     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.08.034     Document Type: Article

References (23)

1. A. Stenzl, N.C. Cowan, and M. De Santis Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2011 1009 1018
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
3. Babjuk M, Burger M, Zigeuner R, et al. Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Uroweb 2013. http://www.uroweb.org/gls/pdf05- TaT1-Bladder-Cancer-LR.pdf.
4. R.J. Sylvester, A.P.M. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477 discussion 475-7
5. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
6. K.D. Linton, D.J. Rosario, and F. Thomas Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance J Urol 189 2013 828 833
7. R.J. Sylvester, W. Oosterlinck, and A.P. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186 2190 quiz 2435
8. I. Berrum-Svennung, T. Granfors, S. Jahnson, H. Boman, and S. Holmang A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences J Urol 179 2008 101 105 discussion 105-6
9. S. Gudjónsson, L. Adell, and F. Merdasa Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study Eur Urol 55 2009 773 780
10. N. Perlis, A.R. Zlotta, J. Beyene, A. Finelli, N.E. Fleshner, and G.S. Kulkarni Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review Eur Urol 64 2013 421 430
11. S.B. Edge, and C.C. Compton The American Joint Committee on Cancer: the 7th edition of the AJCC Cancer Staging Manual and the future of TNM Ann Surg Oncol 17 2010 1471 1474
12. M. Rink, H. Fajkovic, and E.K. Cha Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma Eur Urol 61 2012 854 855
13. P. Mariappan, and G. Smith A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database J Urol 173 2005 1108 1111
14. S. Holmäng, H. Hedelin, C. Anderstrom, E. Holmberg, C. Busch, and S.L. Johansson Recurrence and progression in low grade papillary urothelial tumors J Urol 162 1999 702 707
15. V. Hernandez, E. De La Pena, M.D. Martin, C. Blazquez, F.J. Diaz, and C. Llorente External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer World J Urol 29 2011 409 414
16. J. Fernandez-Gomez, R. Madero, and E. Solsona The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables Eur Urol 60 2011 423 430
17. M. Birkhahn, A.P. Mitra, and A.J. Williams Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles Eur Urol 57 2010 12 20
18. Y.J. Kim, H.Y. Yoon, and J.S. Kim HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling Int J Cancer 133 2013 1135 1142
19. N. Fristrup, B.P. Ulhoi, and K. Birkenkamp-Demtroder Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer Am J Pathol 180 2012 1824 1834
20. M.R. Abern, R.A. Owusu, M.R. Anderson, E.N. Rampersaud, and B.A. Inman Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis J Natl Compr Cancer Netw 11 2013 477 484
21. M.S. Cookson, S.S. Chang, M.G. Oefelein, J.R. Gallagher, B. Schwartz, and K. Heap National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer J Urol 187 2012 1571 1576
22. C.T. Lee, D. Barocas, and D.R. Globe Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases J Urol 188 2012 2114 2119
23. M. Rink, H. Furberg, and E.C. Zabor Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer Eur Urol 63 2013 724 732